A dose-finding study of the combination of pindolol, clopamide and endralazine in the treatment of moderate-to-severe hypertension.
This study compared the efficacy of a beta-blocker, pindolol, and a diuretic, clopamide, plus a vasodilator, endralazine, in the treatment of 30 patients suffering from moderate-to-severe hypertension. Different doses of endralazine were tested. This study showed that hypertension was controlled in 76,7% of patients receiving a combination of pindolol 10 mg and clopamide 5 mg (Viskaldix; Sandoz) plus endralazine 5 mg, and in 90% it was controlled by a combination of pindolol 10 mg, clopamide 5 mg and endralazine 10 mg daily. In 3 patients it was necessary to give pindolol 10 mg, clopamide 5 mg and endralazine 10 mg twice daily. Side-effects occurred in 5 patients, but they were not sufficiently severe for discontinuation of the therapy. There was no difference as regards the blood pressure response in the 15 Black and 15 Indian patients. Tolerance over a period of 14 weeks did not occur. Results of this study suggest that a fixed drug combination of pindolol 10 mg, clopamide 5 mg and endralazine 10 mg once daily could control blood pressure in about 90% of patients suffering from moderate-to-severe hypertension.
D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003005:Clopamide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000008:administration & dosage*; D011724:Pyridazines / Q000008:administration & dosage*; D013997:Time Factors
D000959:Antihypertensive Agents; D011724:Pyridazines; D003005:Clopamide; C014926:BQ 22-708; D010869:Pindolol